CAMBRIDGE, Mass.--(BUSINESS WIRE)--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients through the biology of hypoxia-inducible factor (HIF), today announced financial results for the fourth quarter and full year ended December 31, 2015.
“During 2015, we successfully executed all of our clinical and corporate objectives and we are well-positioned to build on this momentum in 2016,” stated John P. Butler, President and Chief Executive Officer of Akebia.
